Featured Research

from universities, journals, and other organizations

Lung cancer patients with pockets of resistance prolong disease control by 'weeding the garden'

Date:
December 1, 2012
Source:
University of Colorado Denver
Summary:
This study of 65 patients showed that continuing either crizotinib or erlotinib after the treatment of resistant pockets with focused radiation ("weeding the garden") was associated with more than half a year of additional cancer control.

The central skill of cancer is its ability to mutate -- that's how it became cancerous in the first place. Once it's started down that path, it's not so difficult for a cancer cell to mutate again and again. This means that different tumors within a single patient or even different areas within the same cancerous deposit may develop different genetic characteristics. This heterogeneity helps cancer escape control by new, targeted cancer therapy drugs.

Related Articles


Two of these targeted drugs are crizotinib and erlotinib -- they do wonders for the patients whose cancers depend on the basic mutations that these drugs exploit. That is, until pockets of the cancer mutate again, pivoting their dependence away from the original, targeted mutation. Due to continuing mutation, the unfortunate reality is that while crizotinib and erlotinib extend patients' lives, the drugs eventually, inevitably, inexorably stop working.

A University of Colorado Cancer Center study published in the December issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that when pockets of resistant cancer develop, it's often possible to zap these resistant pockets with focused, targeted radiation while continuing crizotinib or erlotinib to maintain control of the majority of the disease that continues to depend on the primary mutation.

"We liken this to weeding the garden," says Andrew Weickhardt, MD, senior clinical fellow at the CU Cancer Center. "In nearly half of patients, when these drugs stop working, they stop working only in a limited number of sites. Given how well these people tolerate the medication, it made sense to us to treat these isolated spots with radiation (or in one case, surgery), and continue the same drug, which was obviously working elsewhere."

This study of 65 patients showed that continuing either crizotinib or erlotinib after the treatment of resistant pockets was associated with more than half a year of additional cancer control.

The benefit was especially robust when the metastatic lung cancer progressed in the brain. The brain is unfortunately a common site of progression because the molecules of crizotinib and erlotinib have difficulty in passing from the bloodstream into the brain, across the so-called blood-brain barrier. Cancer cells sit in the brain as in a robber's cave, hidden away from the drugs.

"We expect using radiation to zap these pockets of cancer in the brain, and then continuing the targeted therapy to become the standard of care," says CU Cancer Center investigator, Ross Camidge, MD, PhD, director of the thoracic oncology clinical program at University of Colorado Hospital.

There was also a smaller but still significant progression-free survival benefit for using this approach in patients whose cancers progressed first outside the brain.

If and when pockets of crizotinib- or erlotinib-resistant lung cancer are detected, "Clinicians should consider using radiation in the body and especially in the brain to weed the garden while continuing the drug, when there is good ongoing control of the cancer in other sites in the body," Weickhardt says.


Story Source:

The above story is based on materials provided by University of Colorado Denver. The original article was written by Garth Sundem. Note: Materials may be edited for content and length.


Journal Reference:

  1. Andrew J. Weickhardt, Benjamin Scheier, Joseph Malachy Burke, Gregory Gan, Xian Lu, Paul A. Bunn, Dara L. Aisner, Laurie E. Gaspar, Brian D. Kavanagh, Robert C. Doebele, D. Ross Camidge. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012; 7 (12): 1807 DOI: 10.1097/JTO.0b013e3182745948

Cite This Page:

University of Colorado Denver. "Lung cancer patients with pockets of resistance prolong disease control by 'weeding the garden'." ScienceDaily. ScienceDaily, 1 December 2012. <www.sciencedaily.com/releases/2012/12/121201085913.htm>.
University of Colorado Denver. (2012, December 1). Lung cancer patients with pockets of resistance prolong disease control by 'weeding the garden'. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2012/12/121201085913.htm
University of Colorado Denver. "Lung cancer patients with pockets of resistance prolong disease control by 'weeding the garden'." ScienceDaily. www.sciencedaily.com/releases/2012/12/121201085913.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com
UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins